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SUMMARY
The T-box transcription factor Brachyury has been considered a cancer-specific marker and a novel oncotarget in solid tumors.
Brachyury overexpression has been described in various cancers, being associated with epithelial–mesenchymal transition, metasta-
sis, and poor prognosis. However, its clinical association with testicular germ cell tumor is unknown. We analyzed the expression of
Brachyury by immunohistochemistry in a series of well-characterized testicular germ cell tumor samples and at transcript level by in
silico analysis. Additionally, we aimed to investigate the clinical significance of Brachyury in testicular germ cell tumor. Brachyury
cytoplasm immunostaining was present in 89.6% (86/96) of cases with nuclear staining observed in 24% (23/96) of testicular germ
cell tumor. Bioinformatics microarray expression analysis of two independent cohorts of testicular germ cell tumors showed similar
results with increased levels of Brachyury in testicular germ cell tumors and metastasis compared with normal testis. Clinically,
Brachyury nuclear staining was statistically associated with lower event-free survival (p = 0.04) and overall survival (p = 0.01) in
intermediate/high-risk testicular germ cell tumors. Univariate analysis showed that Brachyury nuclear subcellular localization was a
predictor of poor prognosis (p = 0.02), while a tendency was observed by multivariate analysis (HR: 3.56, p = 0.06). In conclusion,
these results indicate that Brachyury plays an oncogenic role in testicular germ cell tumors and its subcellular localization in the
nucleus may constitute a novel biomarker of poor prognosis and a putative oncotarget for intermediate/high-risk testicular germ cell
tumor patients.
INTRODUCTION
Brachyury (T) is a T-box transcription factor family with a cen-
tral role in notochord and mesoderm specification (Herrmann
et al., 1990). In the last years, Brachyury has been described by
us and others to be upregulated in several solid tumors, includ-
ing chordoma (Vujovic et al., 2006), lung (Roselli et al., 2012),
breast (Palena et al., 2014), colorectal (Kilic et al., 2011), prostate
(Pinto et al., 2014) cancer, and GIST (Pinto et al., 2016a,b).
Importantly, in these tumors, Brachyury has been reported as an
independent biomarker of poor prognosis (Kilic et al., 2011;
Haro et al., 2013; Palena et al., 2014; Pinto et al., 2014, 2016a,b).
Brachyury acts as a key player in the epithelial–mesenchymal
transition (EMT) and metastasis formation (Fernando et al.,
2010; Imajyo et al., 2012; Shimoda et al., 2012; Du et al., 2014;
Palena et al., 2014; Pinto et al., 2014; Shao et al., 2015; Xu et al.,
2015), also playing an important role in promoting stem cell
properties (Sarkar et al., 2012; Shimoda et al., 2012; Jezkova
et al., 2016; Pinto et al., 2016a,b) and resistance to cytotoxic-
based therapy (Fernando et al., 2010; Roselli et al., 2012; Pinto
et al., 2016a,b). Based on Brachyury oncogenic behavior, an
anti-Brachyury vaccine (GI-6301) was developed and is currently
in Phase II clinical trial (www.clinicaltrials.gov, 2015 –
NCT02383498) for patients with chordoma (Heery et al., 2015).
TGCTs represent the most frequent type of cancer in young
men (Siegel et al., 2016). In non-seminomas, the risk is based on
serum markers levels, primary site, and extrapulmonary metas-
tasis, according to International Germ Cell Cancer Collaborative
Group (IGCCCG) (IGCCCG, 1997). TGCTs present high sensitiv-
ity to first-line platinum-based chemotherapy, and the majority
of patients with metastatic disease may expect to be highly
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responsive, achieving high cure rates, therefore, considered as a
model of curable malignancy (Einhorn, 1990; Feldman et al.,
2008). However, ~15% of cases develop refractory disease, being
the majority of non-seminomas, that fail to be cured following
the first-line treatment (Mead et al., 2005; International Prog-
nostic Factors Study et al., 2010). Thus, identification of novel
biomarkers and prognostic factors for TGCTs, especially in high-
risk group, may be useful for better stratification of patients and
potentially may be used as novel therapeutic targets. Brachyury
is considered a cancer-specific marker, being absent in normal
adult tissues with the exception of testis (Fernando et al., 2010;
Hamilton et al., 2015). A recent study also showed that nuclear
Brachyury expression is present in germ cell tumors (range
between 14% to 74%), yet its clinical–pathological impact was
not evaluated (Miettinen et al., 2015).
Therefore, in this study, we performed an immunohistochem-
istry analysis of Brachyury expression in TGCT and interrogated
its clinical impact. Moreover, we extended our findings using in
silico gene expression analysis of large TGCT datasets. We found
that Brachyury is overexpressed in TGCTs, and its subcellular
nuclear expression may represent a novel biomarker of poor
prognosis in intermediate/high-risk TGCTs and a potential ther-
apeutic target, via GI-6301 anti-Brachyury vaccine.
MATERIALS ANDMETHODS
Tissue samples
A series of paraffin-embedded TGCT primary tissue samples,
composed of 96 TGCTs, was obtained from the Pathology
Department of Barretos Cancer Hospital, Barretos, Brazil. The
samples were collected prior to the use of any systemic treat-
ment. The study was conducted following the national and insti-
tutional ethical policies and was approved by the Barretos
Cancer Hospital Ethical Committee (protocol 676/2013). The
clinicopathological features of TGCTs across different histologi-
cal subtypes are presented in Table 1.
Brachyury immunohistochemistry
The immunohistochemistry analyses were performed as
previously described (Pinto et al., 2014, 2016a,b). Representa-
tive 4-lm-thick sections were subjected to immunohistochem-
istry analysis according to the streptavidin–biotin–peroxidase
complex system (UltraVision Large Volume Detection System
Anti-Polyvalent, HRP; LabVision Corporation), using the pri-
mary antibody raised against Brachyury (sc-20109: Santa Cruz
Biotechnology, Inc). Tumor samples were evaluated for exten-
sion (percentage of cytoplasm-positive cells: 0, negative; 1,
<25% positive cells; 2, 26–50% positive cells; 3, >50% positive
cells) and intensity (0, negative; 1, weak; 2, moderate; 3,
strong) of the immunoreactions. The score used for cytoplasm
staining was the sum of the extension and the staining inten-
sity. Samples with scores 0–2 were considered negative, and
those with scores 3–6 were considered positive. Brachyury
nuclear staining was also evaluated and considered negative
(<25% of the cells with positive nuclei staining) or positive
(≥25% of the cells depicting nuclear staining). The final score
of Brachyury staining was the combination of both cytoplasm
staining and nuclear staining, negative (negative for both sub-
cellular locations) and positive (positive for cytoplasm and/or
nuclear staining).
In silico Brachyury expression analysis: Oncomine and TCGA
databases
Brachyury expression was assessed in three datasets contain-
ing specific information for TGCTs extracted from the Oncomine
database (www.oncomine.org, November 2017) (Rhodes et al.,
2007) [Korkola (Korkola et al., 2006) and Skotheim (Skotheim
et al., 2005)] and from TGCA database (http://cancergenome.
nih.gov/) (Cancer Genome Atlas Research et al., 2013). Brachy-
ury expression was assessed in a total of 10 normal testis
Table 1 Clinicopathological features of the TGCT patients
Characteristics n (%)
Valid TGCT 96
Age (years)
Mean (SD) 28.9 [8.0]
Min-max 18–62
Testis side
Left 46 (48.0)
Right 50 (52.0)
Histology group
Non-seminoma 71 (74.0)
Seminoma 25 (26.0)
Histology
Mixed tumor 27 (28.1)
Seminoma 25 (26.0)
Mixed tumor plus teratoma 18 (18.7)
Embryonal carcinoma 11 (11.5)
Yolk sac tumor 07 (7.3)
Immature teratoma 05 (5.2)
Mature teratoma 1 (1.0)
Choriocarcinoma 2 (2.1)
Serum markers (AJCC)
S0 01 (1.0)
S1 32 (33.3)
S2 25 (26.0)
S3 06 (6.2)
SX 32 (33.3)
Stage (AJCC)
I 6 (6.2)
IS 12 (12.5)
II 31 (32.3)
III 47 (49.0)
Number of metastasis sites
0 18 (18.8)
1 44 (45.8)
2 19 (19.8)
≥3 15 (15.6)
First-line chemotherapy
BEP 77 (80.2)
EP 17 (17.7)
Carboplatin 1 (1.0)
Other 1 (1.0)
Number of first-line chemotherapy cycles
1 8 (8.3)
2 5 (5.2)
3 29 (30.2)
4 54 (56.2)
Chemosensitivity
Responsive 68 (70.8)
Refractory 19 (19.8)
Not applicable 9 (9.4)
IGCCCG risk
Low 46 (47.9)
Intermediate 18 (18.7)
High 13 (13.5)
Not applicable 18 (18.7)
Unknown 1 (1.0)
SD, Standard deviation; AJCC, American Joint Committee on Cancer; IGCCCG,
International Germ Cell Cancer Cooperative Group; BEP, Bleomicine, Etoposide
and Cisplatin; EP, Etoposide e Cisplatin.
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samples, 272 primary TGCTs, and in six metastases. No relevant
clinical information as overall survival, follow-up, treatment,
risk, or stage was available for download.
Statistical analysis
Correlations between Brachyury expression and clinicopatho-
logical data were performed using the chi-square test or Fisher’s
exact test. Cumulative survival probabilities were calculated
using the Kaplan–Meier method. Differences between survival
rates were evaluated by univariate (log-rank test) and multivari-
ate analysis (Cox proportional hazard model). The statistical
analysis was performed using SPSS-v20.0. Simple comparisons
between two different conditions were analyzed using Student’s
t-test in Prism GraphPad-v5.0a. The level of significance in the
statistical analyses is indicated as *p < 0.05, as **p < 0.01 or as
***p < 0.001.
RESULTS
Expression profile of Brachyury in TGCTs
A cohort of 96 TGCTs was submitted to immunohistochem-
istry analysis of Brachyury. We found positive Brachyury
immunostaining, predominantly nuclear, in the seminiferous
tubules of normal testis (Fig. 1a). Overall, 89.6% (n = 86/96) of
TGCTs showed positivity of Brachyury staining (Fig. 1b,c,
Table S1). Specifically, 73.3% (n = 63/86) of the TGCT-positive
tissues depicted Brachyury staining only in the cytoplasm
(Fig. 1b), while 26.7% (n = 23/86) exhibited prevalently nuclear
Brachyury staining, although weakly cytoplasm positivity was
also observed (Fig. 1c).
For statistical analysis, TGCT were classified into negative
(negative for both cytoplasm and nuclear staining; n = 10/96) vs
positive (positive for both cytoplasm and/or nuclear staining;
n = 86/96) or based on Brachyury nuclear staining: nuclear-
negative (76.0%; n = 73/96) vs. nuclear-positive (24.0%;
n = 23/96) (Tables S1 and S2). A statistical analysis was also car-
ried out based on Brachyury subcellular localization: negative
(10.4%; n = 10/96), cytoplasmic (65.6%; n = 63/96), and nuclear
staining (both cytoplasm and nuclear; 24.0%; n = 23/96) (Tables
S1 and S2). Brachyury positivity and Brachyury nuclear subcellu-
lar localization staining were statistically associated with the
presence of altered serum markers (AJCC) S1, S2, S3, or Sx
(Table S1). No association between Brachyury levels and other
clinicopathological variables such as age, histology, stage, num-
ber of metastasis, chemotherapy response, or IGCCCG risk was
found (Table S1).
We were able to identify peritumoral seminiferous tubules in a
subset of cases (n = 23, 24%) where germ cell neoplasia in situ
(GCNIS) was present (Fig. 1d). Nuclear Brachyury staining was
positive in 78.3% of those cases. Only six cases (33.3%) were
nuclear-positive both in germ cell tumor and GCNIS, and there
was no association of nuclear Brachyury staining between
GCNIS and germ cell tumors (p = 1.0).
In silicomicroarray analysis showed BrachyurymRNA levels are
associated with TGCT and metastasis
To extend our study at transcript level, we have performed an
in silico analysis of BrachyurymRNA levels in TGCTs from TCGA
and Oncomine databases. Extracted data represents the only
three datasets with gene expression data available for TGCTs
[TCGA (n = 156); Korkola (n = 110); Skotheim (n = 22)]. RNASeq
analysis showed that Brachyury is overexpressed in TGCTs
(Fig. 2a, TCGA: n = 156 samples). In more, two independent
datasets with expression data for normal testis samples (Korkola
and Skotheim) demonstrate an increased Brachyury expression
in TGCT and metastasis (Fig. 2b and c). To have statistical
(a) (b) (c)
(e)(d)
Figure 1 Immunohistochemical images of Brachyury staining in TGCT. (a) Nuclear Brachyury staining in seminiferous tubules of normal testis. (b) Brachy-
ury-positive staining in the cytoplasm in an embryonal carcinoma. (c) Predominantly and increased Brachyury nuclear staining in a mixed tumor. A weak
cytoplasm staining was also observed. (d) Nuclear Brachyury staining of malignant spermatogonia in intratubular germ cell tumor. (e) Hematoxylin and
eosin staining of intratubular germ cell tumor. Magnification: 4009. TGCT, testicular germ cell tumor.
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power, we have joined the two datasets (testis: n = 10; TGCT:
n = 111; metastasis: n = 6). As observed in Fig. 2d, Brachyury
was statistically upregulated in both TGCTs (p < 0.01) and
metastasis (p < 0.05) samples. Brachyury upregulation was also
observed in three TGCT patients with expression data for both
primary and metastasis samples (Fig. 2e). Moreover, we found
that Brachyury is statistically overexpressed in seminoma
(p < 0.001), mixed (p < 0.001), and intratubular (p < 0.01) germ
cell tumor subtypes (Fig. 2f).
Brachyury nuclear subcellular localization is associated with
poor survival in intermediate/high-risk TGCT
The scarce clinical information from the TCGA database indi-
cates that only four TGCT patients died, in which showed rela-
tive high levels of Brachyury expression (red dots in Fig. 2a).
This information prompts us to explore the prognostic role of
this T-box in our series of TGCT.
Regarding 2-year and 5-year event-free survival (EFS) and
overall survival (OS) and clinicopathological features
(Table S2), we found that lower EFS and OS were significantly
associated with serum markers (AJCC) (p < 0.001 and
p = 0.02), tumor stage (AJCC) (p < 0.001 and p = 0.04), num-
ber of metastasis (p < 0.001 and p = 0.001), chemotherapy
response (p < 0.001 and p < 0.001), and IGCCCG risk
(p < 0.001 and p < 0.001). No association was found with age,
histology or Brachyury staining, and its subcellular localiza-
tion (Table S2). TGCT survival is highly influenced by several
factors as represented in Table S2, including the IGCCCG risk,
which also is associated with other parameters (as tumor
stage, metastasis, and serum markers). Moreover, the interme-
diate- and high-risk TGCTs are more probably resistant to
therapy and urgently need novel prognostic biomarkers in this
specific subgroup of TGCT patients. Then, we analyzed the
prognostic impact of Brachyury expression and compartmen-
talization in the intermediate/high-risk TGCT group (Tables 2
and 3). We observed that staining of Brachyury independently
of its subcellular localization was not associated with poor
survival (Table 2). However, Brachyury positivity in the
Figure 2 Brachyury overexpression in TGCT and metastasis. (a) Brachyury expression analysis from TCGA database (n = 156). Red dots represent the
deceased patients. Expression data represent Level 3 normalization from TCGA portal (expression values were normalized across all samples). (c–d) Brachy-
ury is overexpressed in TGCT and metastatic samples compared with normal testis. Data extracted from (b) Skotheim (n = 22) and (c) Korkola (n = 110)
datasets. (d) Graphical representation of Korkola and Skotheim datasets together (n = 127) showing a statistically significant Brachyury overexpression in pri-
mary TGCT and metastasis. (e) Data from three patients (from Korkola dataset) with both primary and metastasis samples showed an increased expression
of Brachyury in aggressive metastatic tissue compared with primary TGCT. (f) Brachyury is associated with seminoma, mixed, and intratubular subtypes. Data
extracted from Oncomine database from Korkola and Skotheim datasets. TGCT, testicular germ cell tumor.
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nucleus was statistically associated with poor EFS and OS at
2 years and 5 years in intermediate/high-risk TGCT patients
(p = 0.04 and p = 0.01, respectively) (Table 2). As shown in
Fig. 3a, Brachyury nuclear-negative cases present a better
median EFS compared to Brachyury nuclear-positive cases
(18.2 vs. 5.9 months, p = 0.04). The same was shown for med-
ian OS (90.4 vs. 9.8 months, p = 0.01) with median follow-up
of 39.2 months (Fig. 3b). Finally, the multivariate analysis
showed the same tendency, however, did not reach statistical
significance (HR: 3.56, p = 0.06) (Table 3).
In a previous study of the same series, our group showed
that methylation of MGMT and CALCA genes was associated
TGCT poor prognosis. The association of Brachyury expres-
sion and MGMT and CALCA methylation status did not find
any correlation neither in overall TGCT cases (n = 96,
p = 0.53) nor on the intermediate/high-risk group (n = 31,
p = 0.47).
DISCUSSION
Testicular germ cell tumors (TGCT) achieved high cure rates
with platinum-based regimens, yet there is a subset of refractory
patients (IGCCCG, 1997; Gilbert et al., 2009, Popovic et al.,
2015). The tumor markers (alpha fetoprotein and human chori-
onic gonadotrophin) decline rates after 3-week first-line
chemotherapy have been used to predict clinical outcomes in
high-risk TGCT and dose-dense chemotherapy for unfavorable
decline seems to improve survival, although about 40% present a
2-year disease progression (Fizazi et al., 2004, 2014). Besides,
histology, primary tumor location, response to treatment, pro-
gression-free interval after first-line treatment, as well as levels
of tumor markers, and the presence of liver, bone, or brain
metastases at salvage protocols have been used as prognostic
variables. Nevertheless, even in the very low-risk group, about
20% may present a 2-year disease progression (International
Prognostic Factors Study et al., 2010). Therefore, the high-risk
TGCT claims for a biomarker able to guide better therapy with as
low toxicity as possible.
Herein, we proposed, for the first time, the use of Brachyury
nuclear staining as a poor prognostic biomarker for intermedi-
ate/high-risk TGCT patients. All patients with positive Brachy-
ury nuclear staining and intermediate/high-risk according to
the IGCCCG evolved with disease progression before 2 years
and died before 3 years. Our in silico analysis is in agreement
with these results, where four TGCT patients died and showed
relative high levels of Brachyury expression. Brachyury nuclear
positivity has been described mainly in embryonal carcinoma
(74%) and seminoma (45%), and we found 18.2% and 24% in
our setting, respectively (Miettinen et al., 2015). In our cohort,
the mixed tumors were the most common histology subtype
and we were not able to segregate them for comparison
Table 2 Survival of intermediate- or high-risk-
TGCT patients according to clinical features and
Brachyury staining
Clinical features Patients n Event-free survival (%) Overall survival (%)
2 years 5 years p-value† 2 years 5 years p-value†
TGCT 31 32.3 27.6 66.5 53.7
Age (years)
<28.9 20 32.5 26.0 0.84 64.3 50.5 0.64
≥28.9 11 31.8 31.8 70.1 58.4
Histology group
Non-seminoma 26 34.9 29.9 0.68 67.5 57.3 0.44
Seminoma 5 20.0 20.0 60.0 40.0
Histology
Seminoma 5 20.0 20.0 0.18 60.0 40.0 0.11
Mixed tumor 8 37.5 37.5 50.0 50.0
Mixed tumor plus teratoma 7 28.6 0.0 64.3 64.3
Embryonal carcinoma 4 75.0 75.0 100.0 100.0
Yolk sac tumor 4 0.0 0.0 66.7 0.0
Immature teratoma 2 0.0 0.0 100.0 100.0
Choriocarcinoma 1 0.0 0.0 0.0 0.0
Mature teratoma 0 n/a n/a n/a n/a
Serum markers (AJCC)
S0 0 n/a n/a 0.001 n/a n/a 0.56
S1 3 0.0 0.0 66.7 66.7
S2 13 46.2 36.9 68.4 59.8
S3 5 0.0 0.0 40.0 40.0
SX 10 35.0 35.0 78.8 50.6
Chemosensitivity
Responsive 17 62.6 53.6 <0.001 69.5 69.5 0.17
Refractory 14 0.0 0.0 63.5 31.7
Brachyury staining
Negative 3 33.3 33.3 0.95 66.7 66.7 0.81
Positive 28 32.1 26.8 66.3 52.3
Brachyury Nuclear staining only
Negative 27 37.3 31.9 0.04 73.5 62.9 0.01
Positive 4 0.0 0.0 25.0 0.0
Brachyury subcellular localization
Negative 3 33.3 33.3 0.12 66.7 66.7 0.04
Only cytoplasm 24 37.8 31.5 74.2 62.3
Nucleus ( cytoplasm) 4 0.0 0.0 25.0 0.0
†Log-rank test; n/a – Not applicable.
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analysis, which prelude any kind of associations with tumor
histology (p = 0.91). However, by in silico analysis, we found
that high levels of Brachyury are associated with seminoma,
mixed, and intratubular germ cell subtypes. We found
intratubular GCNIS in 23 cases, and nuclear Brachyury was
positive in 78.3%, although there was no association of
nuclear Brachyury staining between GCNIS and germ cell
tumors. The hypothesis of Brachyury as an early TGCT
tumorigenic event of should be tested, but it seems that Bra-
chyury remains as an important proliferative drive during
TGCT tumor progression. Unfortunately, peritumoral
seminiferous tubules were underrepresented in our cohort
hampering any conclusion on this topic.
Our results are in accordance with the findings in other tumor
types, such as GIST and prostate cancer, in which we demon-
strated the association of Brachyury overexpression with tumor
aggressiveness and presence of metastasis (Pinto et al., 2014,
2016a,b). In primary lung carcinoma, Brachyury mRNA expres-
sion was a significant predictor of poor prognosis for 5-year
disease-free survival and overall survival (Haro et al., 2013).
Brachyury mRNA and protein expression was also analyzed in
human breast carcinomas, and it was associated with tumor
recurrence and distant metastasis (Palena et al., 2014). These
data corroborate with the upregulation of Brachyury observed
in more advanced TGCT according to our in silico analysis.
The impact of Brachyury in the cytoplasm has been described
in several tumor types, including colorectal cancer (Kilic et al.,
2011), prostate cancer (Pinto et al., 2014), and GIST (Pinto
et al., 2016a,b), and to be associated with poor prognosis. In
our series of TGCT, we did not find any association with the
clinical–pathological data. Previously, we have hypothesized
that Brachyury protein in the cytoplasm can i) interact with
cofactors to regulate oncogenic pathways, as described to other
transcription factors (Green & Kroemer, 2009; Lau & Ronai,
2012); or ii) be a consequence of a dynamic process of protein
shuttling between cytosol and nucleus. In this particular case,
we hypothesize that Brachyury is accumulated in the cytosol of
cancer cells as a consequence of enhanced translation mecha-
nisms. As so, Brachyury presence in the cytosol can be a surro-
gate marker of TGCT progression. Clearly, there is much more
to fully understand the role of Brachyury in the cytoplasm and
further studies are warranted.
In our cohort of TGCT patients, we recently reported that well-
known hallmarks of cancer, as microsatellite instability (MSI),
V600E BRAF, and TERT promoter mutations, are not present
Table 3 Univariate and multivariate overall survival analysis of intermedi-
ate- or high-risk-TGCT patients by Cox model
Variable Univariate analysis Multivariate analysis
Hazard
ratio
95% CI p-value Hazard
ratio
95% CI p-value
Age (years)
<28.9 1 *
≥28.9 0.75 0.23–2.46 0.64
Histology group
Non-
seminoma
0.60 0.16–2.22 0.44
Seminoma 1 *
Serum markers (AJCC)
S1 0.48 0.05–4.70 0.53
S2 0.38 0.09–1.66 0.20
S3 1 *
SX 0.40 0.08–1.82 0.23
Chemosensitivity
Responsive 1 * 1 *
Refractory 2.15 0.70–6.63 0.180 1.58 0.46–5.34 0.45
Brachyury Nuclear staining only
Negative 1 * 1 *
Positive 4.30 1.25–15.14 0.02 3.56 0.93–13.55 0.06
95% CI – 95% confidence interval. *, multivariate analysis.
Figure 3 Brachyury is a novel biomarker of poor prognosis in intermediate/high-risk TGCT. Kaplan–Meier analysis of event-free (a) and overall survival
(b) according to Brachyury nuclear staining. Patients with Brachyury nuclear staining present worse survival probabilities compared with nuclear-negative
patients.
6 Andrology, 1–8 © 2018 American Society of Andrology and European Academy of Andrology
F. Pinto et al. ANDROLOGY
(Carcano et al., 2016a,b). Recently, Bagrodia et al. (2016) found
TP53 pathway alterations associated with poor risk according to
IGCCCG, especially by amplification of MDM2, an E3 ubiquitin-
protein ligase that negatively regulates TP53. Further, TP53 and
MDM2 alterations were associated with worse outcomes, inde-
pendent of the IGCCCG model, in the same study. Moreover, our
group has described MGMT and CALCA promoter methylation
as associated with poor prognosis in TGCT (Martinelli et al.,
2016). New MDM2 inhibitors have been developed (Zhao et al.,
2015), as well as a second generation of DNA methylation inhibi-
tor (Albany et al., 2017). Together with anti-Brachyury vaccine
(GI-6301), those new drugs open a new window of possibilities
to treat the high-risk TGCT with targetable functional molecules.
Our cohort of patients is representative of TGCT, and well-
known prognostic factors, such as serum markers, stage,
chemosensitivity, number of metastasis sites, and IGCCCG
model, were statistically significant. However, the results from
intermediate/high-risk setting have limited inference due to
small exploratory sample (n = 31). Moreover, the confidence
interval of Brachyury nuclear staining in multivariate analysis is
rather large (95% CI: 0.93–13.55) and the number of events is low
to achieve confident and meaningful conclusions, despite the
hazard ratio significant values. Therefore, further studies with a
higher number of patients and with a broader representation of
the distinct histological and clinical subtypes are needed to con-
solidate the prognostic role of Brachyury in TGCT. In conclusion,
these results indicate that Brachyury plays an oncogenic role in
TGCTs and its subcellular nuclear localization constitutes a
novel biomarker of poor prognosis and a putative target for ther-
apy in intermediate/high-risk TGCT patients.
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